Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 3Hodgkin Disease 3Multiple Myeloma 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Neoplasms by Site 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia 1Bronchiolitis Obliterans Syndrome 1

Interventions

ibrutinib 5ofatumumab 4Imatinib Mesylate 4Dasatinib 4nilotinib 3fludarabine 3bosutinib 3asciminib 3Rituximab 3Cyclophosphamide 3ruxolitinib 2obinutuzumab 2Sirolimus 2Mycophenolic Acid 2KW-2478 2Filgrastim 2Alemtuzumab 2posaconazole 1ponatinib 1pegfilgrastim 1oblimersen 1montelukast 1mocetinostat 1milatuzumab 1lonafarnib 1fenebrutinib 1abexinostat 1Whole-Body Irradiation 1Voriconazole 1Vision, Ocular 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bronchiolitis Obliterans Syndrome × abexinostat × Other hematologic neoplasm × Clear all
NCT01149668 2013-06-19

A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer

Pharmacyclics LLC.

Phase 1 Completed
7 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Bronchiolitis Obliterans Syndrome, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡